First round open questions
| Q1. Follow-up definition | The term ‘follow-up’ in clinical trials can have different interpretations dependent on the role of the researcher. Please provide your definition of the term ‘follow-up’ in relation to cancer clinical trials. |
| Q2. Barriers and burdens | Please describe the phenomena you encounter in your role within cancer clinical research, which you perceive as barriers or burdens to effective trial implementation and delivery. Please feel free to list as many issues or concepts as you wish. These could relate to local, departmental or regional factors as well as cultural, resource and study design elements. |
| Q3. Complexity | Please provide your analysis of complexity in terms of delivering cancer clinical trials. This could include the complex nature of the disease or interactions involved in managing the treatment and care pathway for a cancer patient participating in a clinical trial. Please feel free to suggest as many themes as you wish. |
| Q4. Capacity factors | Please describe factors affecting your capacity to support and deliver cancer clinical trials within the NHS. These can be elements relative to your specific role, organisation or more global factors. Please list as many considerations as you wish. |
| Q5. Top priorities | Please suggest your top three strategic priorities for the future delivery of cancer clinical trials in the NHS. |
| Q6. Effective practice | Please provide your views on existing elements of cancer clinical research practice within the NHS, which contribute to or demonstrate efficient trial delivery and practice. |
| Q7. Additional considerations | Please add any additional elements you feel should be considered by the Delphi panel in relation to reviewing the operational delivery, follow-up and complexity of cancer clinical trials. |
NHS, National Health Service.